Dividend Calendar: Week of April 6, 2026

The week of April 6, 2026, presents income investors with an attractive lineup of dividend-paying stocks across multiple sectors. This week’s calendar features 15 companies offering yields ranging from 2.14% to 6.07%, with pharmaceutical and telecommunications stocks leading the high-yield category.

Healthcare and pharmaceutical companies dominate this week’s dividend activity, with Pfizer (PFE) offering the highest yield at 6.07%. The telecommunications sector is also well-represented, with both Verizon (VZ) and AT&T (T) providing substantial yields for income-focused portfolios.

Ex-Dividend Dates This Week

High-Yield Opportunities

Income investors seeking higher yields will find several attractive options this week. Pfizer leads with a 6.07% yield, reflecting the pharmaceutical giant’s commitment to shareholder returns. Verizon follows closely at 5.54%, offering telecommunications exposure with a substantial dividend payment of $2.74 per share.

Bristol-Myers Squibb rounds out the top three high-yielders at 4.19%, providing another pharmaceutical option for dividend-focused portfolios. These higher-yielding stocks may appeal to investors seeking current income, though it’s important to evaluate the sustainability of these dividend payments alongside company fundamentals.

Blue-Chip Dividend Aristocrats

Several dividend aristocrats and long-term dividend growth champions appear on this week’s calendar. Johnson & Johnson, despite offering a more modest 2.14% yield, represents decades of consecutive dividend increases. The Coca-Cola Company and Procter & Gamble also feature prominently, offering yields of 2.69% and 2.95% respectively.

These established dividend payers typically provide more predictable income streams and have historically demonstrated the ability to grow their dividends over time, making them attractive for long-term income strategies.

Sector Diversification

This week’s dividend calendar offers excellent sector diversification opportunities. Healthcare and pharmaceuticals are well-represented with PFE, BMY, ABBV, MRK, GILD, and JNJ. Energy sector exposure comes through CVX and XOM, while consumer staples are represented by PEP, PG, and KO. Financial services appear through USB and WFC, and telecommunications through VZ and T.

How to Use This Dividend Calendar

This dividend calendar is designed as a research starting point, not a buy list. Before acting on any name below, walk through three checks in order. First, confirm the ex-dividend date against the company’s investor-relations page — the dates in this calendar reflect the schedule announced at the time of publication, and boards routinely reset them mid-quarter. Second, compare the announced dividend against the trailing four quarters of payouts to spot freezes or cuts. A 6% headline yield looks attractive in isolation, but if the company cut its dividend two quarters ago, the current yield is a lagging indicator of deterioration, not a green light.

Third, size any new position with the dividend yield in mind, not against it. For most retail investors, a single dividend stock above a 4% yield should not exceed 2-3% of the portfolio; mid-yield names between 2.5% and 4% can run higher; sub-2.5% yields are typically held for total-return reasons (capital appreciation plus modest income) rather than for the dividend itself. These ranges are not rules — they reflect the empirical observation that yield concentrates risk, and concentrated dividend exposure tends to underperform on risk-adjusted basis when the underlying business turns.

Sector Concentration Analysis

The week of April 6, 2026 skews heavily toward healthcare and pharmaceuticals, with six of the fifteen names falling into that bucket: Pfizer, Bristol-Myers Squibb, AbbVie, Merck, Gilead Sciences, and Johnson & Johnson. That sector tilt is more concentrated than the typical week, where healthcare usually accounts for three to four names out of fifteen. Two forces drive this. First, Q1 is a heavy dividend-payment window for pharma because fiscal-year-end planning tends to push board meetings into late February and early March, with payment dates landing four to six weeks later. Second, 2025-2026 was a difficult earnings year for the sector (drug-pricing pressure, IRA negotiation round two, GLP-1 margin compression on adjacent therapeutic areas), which pushed more pharma boards toward signaling shareholder-return discipline rather than reinvestment — dividend announcements are one of the cheapest signals available.

Telecommunications is the second-most-concentrated sector with two names — Verizon and AT&T — both yielding above 3.9%. The sector has consolidated meaningfully since 2022 (T-Mobile’s mid-band 5G build-out forced capex discipline on incumbents), and the duopoly that emerged is now returning cash to shareholders rather than building network. Financials round out the concentrated sectors with U.S. Bancorp and Wells Fargo. Energy (Chevron, Exxon Mobil) and consumer staples (PepsiCo, Procter & Gamble, Coca-Cola) provide the counterweight — both sectors are present in roughly their typical weekly share, and both offer diversification benefits when paired against a healthcare-heavy lineup.

Yield Tiers and Risk Considerations

Sorting this week’s calendar by yield produces three natural tiers. The high-yield tier (above 4.5%) contains Pfizer at 6.07% and Verizon at 5.54% — both are mature, slow-growth businesses where the dividend represents the bulk of total return. Bristol-Myers Squibb at 4.19% sits at the boundary; pharma generally pays higher yields than the broader market when pipelines are thin or patents are expiring, and the 4.19% on BMY is a soft signal that the market is pricing in pipeline risk. None of these are distressed credits in the traditional sense — Pfizer’s payout ratio is sustainable, Verizon’s leverage is manageable post-SpectrumCo — but the yields reflect market skepticism about forward growth, not market enthusiasm about current income.

The mid-yield tier (2.5% to 4%) is the most crowded on this calendar: AT&T, U.S. Bancorp, PepsiCo, Chevron, AbbVie, Procter & Gamble. These are typically dividend-growth names with established track records of annual increases. The risk in this tier is not that the dividend gets cut — most have raised for 25+ consecutive years — but that the share price stagnates and the yield-on-cost advantage erodes. The low-yield tier (below 2.5%) — Merck, Coca-Cola, Exxon Mobil, Gilead Sciences, Wells Fargo, Johnson & Johnson — is dominated by total-return names where the dividend is a small contributor to returns and the investment thesis rests on capital appreciation. Johnson & Johnson’s 2.14% yield looks low against the calendar’s headline numbers, but JNJ’s track record of 60+ consecutive annual dividend increases is the differentiator — the yield is low because the price has compounded steadily, not because the dividend is small.

Timing the Ex-Dividend Trade

The ex-dividend date is the cut-off for receiving the upcoming dividend payment. Investors who own shares before the ex-date receive the dividend; investors who buy on or after the ex-date do not. The mechanics matter for two reasons. First, the stock typically trades down by approximately the dividend amount on the ex-date — the share price reflects the upcoming cash outflow — so a naive buy on the ex-date “to capture the dividend” actually purchases a position that has just lost that amount in market value. The dividend is real, but it is offset by the price drop, and the trade is closer to neutral than it appears.

Second, the weeks leading up to an ex-date are when the most aggressive dividend capture happens, and that flow can compress option premiums and push implied volatility lower. For investors who already hold the stock, the only decision is whether to hold through the ex-date (yes, if the position is sized appropriately and the dividend is consistent with the strategy) or trim the position ahead of it. For investors considering a new entry, the post-ex-date pullback is often a better entry point than the pre-ex-date run-up, particularly in names where the yield itself is not the reason for the position. The dividend calendar tells you when the cash flows; the rest of the analysis tells you whether the position belongs in the portfolio at all.

This information is for educational purposes only and should not be considered investment advice. Dividend payments and yields are subject to change, and past performance does not guarantee future results. Investors should conduct their own research and consider their individual financial circumstances before making investment decisions.